Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Kiora Pharmaceuticals, Inc. Common Stock

KPRX

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.934 – $1.02
Volume 52,754
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.34M
Price / earnings
—
Price / book
0.28×
Price / sales
4.34×
EV / sales
-1.23×
EV / EBITDA
0.14×

Profitability

Earnings per share
-$2.88
Return on assets
-57.04%
Return on equity
-83.44%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.91×
Quick ratio
7.91×
Cash ratio
2.21×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.9M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KPRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1M$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$1M$0$0$0$0$0$0$0
Selling, general and administrative$1.58M$1.38M$1.61M$1.46M$1.44M$1.35M$1.49M$1.33M
Research and development$1.95M$2.08M$2.12M$2.93M$2.73M$2.59M$2.53M-$83.66K
Total operating expenses$2.69M$2.21M$2.51M$7.31M$794.44K$2.4M$2.33M$2.56M
Operating income-$1.69M-$2.21M-$2.51M-$7.31M-$794.44K-$2.4M-$2.33M-$2.56M
Interest expense$0$146.23K$0-$19.96K$0$225.24K$0-$21.45K
Income before taxes-$1.58M-$2.08M-$2.42M-$7.17M-$616.32K-$2.26M-$2.07M-$2.16M
Income taxes$165K$0$0-$649.97K-$643.13K-$112.06K$123.01K$2.07M
Net income-$1.75M-$2.08M-$2.42M-$6.52M$26.81K-$2.15M-$2.19M-$4.22M
Net income attributable to common shareholders-$1.75M-$2.08M-$2.42M-$6.52M$26.81K-$2.15M-$2.19M-$4.22M
EBITDA-$1.68M-$2.2M-$2.5M-$2.68M-$783.89K-$2.39M-$2.33M-$550.77K
Basic earnings per share-$0.28-$0.34-$0.58-$1.56$0.01-$0.54-$0.52-$1.00
Diluted earnings per share-$0.28-$0.34-$0.58-$1.69$0.01-$0.54-$0.52-$1.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Benzinga

HC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Kiora Pharmaceuticals (NASDAQ:KPRX) and raise its price target from $3.50 to $2.00. Shares of Kiora Pharmaceuticals are trading down 0.84% over the last 24 hours, at $0.66 per share. A move to $2.00 would account for a 202.57% increase from the current share price. About Kiora Pharmaceuticals Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in ...Full story available on Benzinga.com

Benzinga

Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results. Skechers said fourth-quarter revenue increased 4.4% year-over-year to $1.96 billion, which missed the consensus estimate of $2.03 billion, according to Benzinga Pro. The company reported quarterly earnings of 56 cents per share, which beat analyst estimates of 54 cents per share. Skechers shares fell 6.9% to $59.21 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares jumped 77.6% to $4.28. Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million. Minim, Inc. (NASDAQ: MINM) shares rose 34.4% to $6.76 after gaining more than 22% on Thursday. Remark Holdings, Inc. (NASDAQ: MARK) shares climbed 33% to $0.6802. Kopin Corporation (NASDAQ: KOPN) jumped 30% to $2.4050. BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 26.3% to $2.73. Mountain Crest Acquisition Corp. IV (NASDAQ: MCAF) gained 23% to $14.65. Tyra Biosciences, Inc. (NASDAQ: TYRA) gained 21.8% to $15.84. Tyra Biosciences announced a $200 million private placement financing. Meta Platforms, Inc. (NASDAQ: META) rose 18.9% to $469.34 as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share. CCSC Technology International Holdings Limited (NASDAQ: CCTG) gained 18.2% to $4.6099 after dipping around 82% on Thursday. Roma Green Finance Limited (NASDAQ: ROMA) gained 15.8% to $0.8697 after gaining around 5% on Thursday. Deckers Outdoor Corporation (NYSE: DECK) surged 14% to $879.03 after reporting better-than-expected third-quarter financial results. Trugolf, Inc. (NASDAQ: TRUG) shares jumped 14% to ...

Benzinga

Why Meta Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share. The company also announced a $50 billion increase to its share repurchase authorization. Meta shares climbed 16.5% to $460.02 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers CCSC Technology International Holdings Limited (NASDAQ: CCTG) gained 55.1% to $6.05 in pre-market trading after dipping around 82% on Thursday. Trugolf, Inc. (NASDAQ: TRUG) shares jumped 33.1% to $1.77 in pre-market trading after dipping 55% on Thursday. Roma Green Finance Limited (NASDAQ: ROMA) gained 25.2% to $0.94 in pre-market trading after gaining around 5% on Thursday. Jiuzi Holdings, Inc. (NASDAQ: JZXN) shares gained 20% to $0.84 in pre-market trading. C3is Inc. (NASDAQ: CISS) shares rose 18.8% to $0.1625 in pre-market trading. S.H.N. Financial recently reported a 9.1% stake in the company. Minim, Inc. (NASDAQ: MINM) shares rose 18.7% to $5.97 in pre-market trading after gaining more than 22% on ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 11, 20241-for-9reverse split
Sep 27, 20221-for-40reverse split
Aug 30, 20191-for-15reverse split